Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Panacos Pharmaceuticals (PANC) -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (23)	6/28/2007 4:17:45 PM
From: tuck	Read Replies (1) \| Respond to of 53

>>Panacos Secures $20 Million Debt Financing Thursday June 28, 4:02 pm ET WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (NASDAQ:PANC - News), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, announced that it has closed a $20 million term loan agreement today with Hercules Technology Growth Capital, Inc. (NASDAQ: HTGC - News). Under the terms of the loan agreement, Hercules has advanced $10 million to the Company immediately upon closing. The Company plans to draw the remaining $10 million prior to September 30, 2007. "This financing extends Panacos' cash runway in a relatively non-dilutive form, and provides us with additional strategic flexibility as we continue to advance our pipeline of antiviral programs," said Alan W. Dunton, M.D., Panacos' Chief Executive Officer. "We are pleased to enter this relationship with Hercules, and will benefit from their experience and expertise in the biopharmaceutical industry." Under the agreement, only interest payments will be required for the first 12 months. Thereafter, the balance will be payable in equal monthly installments of principal and interest for 30 months. As part of the transaction, the Company issued to Hercules a five-year warrant to purchase 646,900 shares of the Company's common stock at an exercise price per share of $3.71.<< snip This isn't too bad, and was the risk I was waiting for to pass. Seems stable after hours. Considering putting in lowball bid . . . Cheers, Tuck